Leukemia (AML, CLL, CML & ALL)

Acute myeloid leukemia (AML) now features targeted therapies for IDH1/2 and FLT3 mutations, as well as venetoclax-based combinations. Chronic lymphocytic leukemia (CLL) has been transformed by BTK inhibitors and the BCL-2 inhibitor venetoclax. Chronic myeloid leukemia (CML) is managed with BCR-ABL tyrosine kinase inhibitors including asciminib. Acute lymphoblastic leukemia (ALL) is treated with intensive chemotherapy, blinatumomab, and inotuzumab ozogamicin.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Leukemia (AML, CLL, CML & ALL)

• Venetoclax (Venclexta) — BCL-2 Inhibitor
• Azacitidine (Vidaza) — Antimetabolite
• Decitabine (Dacogen) — Antimetabolite
• Ivosidenib (Tibsovo) — Other
• Enasidenib (Idhifa) — Other
• Midostaurin (Rydapt) — FLT3 Inhibitor
• Gilteritinib (Xospata) — FLT3 Inhibitor
• Gemtuzumab ozogamicin (Mylotarg) — Antibody-Drug Conjugate
• Ziftomenib (Komzifti) — Other
• Ibrutinib (Imbruvica) — Tyrosine Kinase Inhibitor
• Acalabrutinib (Calquence) — BTK Inhibitor
• Zanubrutinib (Brukinsa) — BTK Inhibitor
• Pirtobrutinib (Jaypirca) — BTK Inhibitor
• Obinutuzumab (Gazyva) — Monoclonal Antibody
• Rituximab (Rituxan) — Monoclonal Antibody
• Ofatumumab (Arzerra) — Monoclonal Antibody
• Imetelstat (Rytelo) — Other
• Asciminib (Scemblix) — Tyrosine Kinase Inhibitor
• Dasatinib (Sprycel) — Tyrosine Kinase Inhibitor
• Nilotinib (Tasigna) — Tyrosine Kinase Inhibitor
• Ponatinib (Iclusig) — Tyrosine Kinase Inhibitor
• Imatinib (Gleevec) — Tyrosine Kinase Inhibitor
• Blinatumomab (Blincyto) — Monoclonal Antibody
• Inotuzumab ozogamicin (Besponsa) — Antibody-Drug Conjugate
• Nelarabine (Arranon) — Antimetabolite